Molecular Pattern of Breast Cancer Among A Series of Egyptian Patients
Research in Oncology
Triple negative (TN) breast cancer has a bad prognosis. It is associated with a poor progressionfree and overall survivals. Accordingly, we explored the outcome of different molecular subtypes among a series of Egyptian breast cancer patients. Methods: A total of 661 non-metastatic breast cancer patients' files were reviewed from Kasr Al-Aini Center of Clinical Oncology and Nuclear Medicine of Cairo University between January 2005 and December 2010. Data were analyzed for age; menopausal
... ; menopausal status, tumour size, nodal status, pathological type, grade; estrogen status, progesterone status, and human epidermal growth factor receptor 2 (HER2) status. Disease free survival (DFS) was the primary end point. results: The median age was 50 years. 50.4% of patients were premenopausal, 93.1% had invasive duct carcinoma, 93.3% had grade II tumours, 79.4% had early tumours (T1&T2), 70.4% had positive lymph nodes, 51.7% had luminal A subtype, 21.3% had luminal B, 10.2% had Her2-enriched and 16.6% had TN. Disease free survival after 3 years for each subtype was 87.8% for luminal A, 86% for luminal B, 69% for TN and 66% for HER2 (P= .008). The 3-year disease-free survival was significantly better for postmenopausal patients 92.1% as compared with premenopausal patients 80.1% (P= <0.001), with early tumours (T1&T2) 92.1% & 87.3% respectively as compared with advanced tumours (T3+T4) 80.1% (P= <0.001), LN negative (N0) 98.1% as compared with LN positive (N1+N2) 85.2% and (N3) 68% (P= <0.001), (ER) positive 90.2% as compared with (ER) negative 78.2% (P= <0.001), (PR) positive 90% as compared with (PR) negative 80.2% (P= 0.003), non TNBC 89.8% as compared with TN 72.1% (P= 0.012). The 2 & 3 year disease-free survival for TN patients (N= 31) who received adjuvant platinum-based chemotherapy was 81% & 46% respectively and for those who received adjuvant non-platinum (N=74) chemotherapy was 84% & 78% respectively (log rank P-value = 0.135). conclusions: In our series of Egyptian patients, luminal breast cancer subtypes (A& B) had the highest 3-year disease-free survival followed by TN then Her2-enriched type. Adjuvant platinum based chemotherapy had no impact on the 3-year disease-free survival when compared with non-platinum chemotherapy in TN patients.